{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:06:26Z","timestamp":1790629586189,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ygyno.2018.10.023","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T09:06:58Z","timestamp":1541408818000},"page":"416-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review"],"prefix":"10.1016","volume":"152","author":[{"given":"Mary M.","family":"Mullen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.10.023_bb0005","first-page":"2018","article-title":"Ovarian Cancer Statistics","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"9375","key":"10.1016\/j.ygyno.2018.10.023_bb0010","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2018.10.023_bb0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ygyno.2018.10.023_bb0020","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2018.10.023_bb0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.023_bb0030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.10.023_bb0035","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2018.10.023_bb0040","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.10.023_bb0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.10.023_bb0050","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2018.10.023_bb0055","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Bois","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2018.10.023_bb0060","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","volume":"36","author":"Coleman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.023_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-14-22","article-title":"Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study","volume":"14","author":"van de Laar","year":"2014","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2018.10.023_bb0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther Adv Med Oncol."},{"issue":"29","key":"10.1016\/j.ygyno.2018.10.023_bb0075","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2018.10.023_bb0080","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.10.023_bb0085","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2018.10.023_bb0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00280-007-0617-2","article-title":"Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I\/II study","volume":"62","author":"Koensgen","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.ygyno.2018.10.023_bb0095","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/annonc\/mdt406","article-title":"Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data","volume":"24","author":"Raja","year":"2013","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.10.023_bb0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.10.023_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6\u201312\u202fmonths) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.10.023_bb0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdq353","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval","volume":"22","author":"Kaye","year":"2011","journal-title":"Ann. Oncol."},{"issue":"29","key":"10.1016\/j.ygyno.2018.10.023_bb0115","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study","volume":"35","author":"Pignata","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.10.023_bb0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ctrv.2011.06.004","article-title":"Targeting angiogenesis in ovarian cancer","volume":"38","author":"Schmitt","year":"2012","journal-title":"Cancer Treat. Rev."},{"issue":"17","key":"10.1016\/j.ygyno.2018.10.023_bb0125","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.10.023_bb0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.023_bb0135","article-title":"Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17","volume":"5506","author":"Pignata","year":"2018","journal-title":"ASCO"},{"issue":"10023","key":"10.1016\/j.ygyno.2018.10.023_bb0140","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2018.10.023_bb0145","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/JCO.2017.35.15_suppl.5506","article-title":"Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer","volume":"35","author":"Ledermann","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2018.10.023_bb0150","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/cncr.30657","article-title":"Quality of life with cediranib in relapsed ovarian cancer: the ICON6 phase 3 randomized clinical trial","volume":"123","author":"Stark","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2018.10.023_bb0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","article-title":"Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2","volume":"143","author":"Monk","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.10.023_bb0160","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2018.01.010","article-title":"Management of the toxicities of common targeted therapeutics for gynecologic cancers","volume":"148","author":"Gunderson","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.023_bb0165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fonc.2013.00228","article-title":"The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells","volume":"3","author":"De Lorenzo","year":"2013","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2018.10.023_bb0170","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.ygyno.2018.10.023_bb0175","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly (ADP-ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7035","key":"10.1016\/j.ygyno.2018.10.023_bb0180","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ygyno.2018.10.023_bb0185","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2018.10.023_bb0190","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2018.10.023_bb0195","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2018.10.023_bb0200","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10106","key":"10.1016\/j.ygyno.2018.10.023_bb0205","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2018.10.023_bb0210","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"7353","key":"10.1016\/j.ygyno.2018.10.023_bb0215","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.ygyno.2018.10.023_bb0220","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2018.10.023_bb0225","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2007.11.3902","article-title":"Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway","volume":"26","author":"Weberpals","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.10.023_bb0230","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2018.10.023_bb0235","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2018.10.023_bb0240","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2018.10.023_bb0245","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and BRCA 1\/2 mutation (SOLO2\/ENGOT-OV21): a double randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2018.10.023_bb0250","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.10.023_bb0255","series-title":"Highlights of Prescribing Information","article-title":"Lynparza (olaparib) tablets, for oral use","author":"FDA","year":"2014"},{"issue":"1","key":"10.1016\/j.ygyno.2018.10.023_bb0260","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.10.023_bb0265","article-title":"Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2","volume":"145","author":"Konecny","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2018.10.023_bb0270","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.10.023_bb0275","series-title":"Highlights of Prescribing Information","article-title":"Rubraca (rucaparib) tablets, for oral use","author":"FDA","year":"2016"},{"key":"10.1016\/j.ygyno.2018.10.023_bb0280","series-title":"Highlights of prescribing information","article-title":"Zejula (niraparib) capsules, for oral use","author":"FDA","year":"2017"},{"key":"10.1016\/j.ygyno.2018.10.023_bb0285","series-title":"Paper presented at: The Society of Gynecologic Oncology Annual Meeting on Women's Cancer","article-title":"ENGOT-OV16\/NOVA: results of secondary efficacy endpoints of niraparib maintenance therapy in ovarian cancer","author":"Mahner","year":"2017"},{"issue":"suppl_5","key":"10.1016\/j.ygyno.2018.10.023_bb0290","doi-asserted-by":"crossref","first-page":"v330","DOI":"10.1093\/annonc\/mdx372","article-title":"Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: results from the ENGOT-OV16\/NOVA Trial","volume":"28","author":"Oza","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2018.10.023_bb0295","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1200\/JCO.2017.35.15_suppl.5534","article-title":"Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC)","volume":"35","author":"Matulonis","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.023_bb0300","series-title":"Presented at: SGO Annual Meeting on Women's Cancer; March 24\u201327, 2018. New Orleans","article-title":"Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16\/NOVA phase III trial","author":"Lord","year":"2018"},{"issue":"6","key":"10.1016\/j.ygyno.2018.10.023_bb0305","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju089","article-title":"Phase I\/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses","volume":"106","author":"Lee","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"17","key":"10.1016\/j.ygyno.2018.10.023_bb0310","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/0008-5472.CAN-11-1227","article-title":"Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas","volume":"71","author":"Kummar","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2018.10.023_bb0315","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-11-2821","article-title":"A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas","volume":"18","author":"Kummar","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"Suppl.: abstract 3000","key":"10.1016\/j.ygyno.2018.10.023_bb0320","article-title":"Phase I study of the safety, pharmacokinetics and pharmacodynamics of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combintion with irinotecan (CPT-111) in patients with advanced solid tumors","volume":"299","author":"Lorusso","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.: abstract 3041","key":"10.1016\/j.ygyno.2018.10.023_bb0325","article-title":"Phase I trial of veliparib (ABT-888): a poly (ADP-ribose) polymerase (PARP) inhibitor in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors","volume":"29","author":"Tan","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.10.023_bb0330","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ygyno.2017.12.029","article-title":"Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies","volume":"148","author":"Gray","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2018.10.023_bb0335","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1158\/1078-0432.CCR-08-1223","article-title":"Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors","volume":"14","author":"Plummer","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.10.023_bb0340","series-title":"Proceedings from the European Cancer Congress","article-title":"A phase I study of oral rucaparib in combination with carboplatin","author":"Roxburgh","year":"2013"},{"issue":"7","key":"10.1016\/j.ygyno.2018.10.023_bb0345","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2017.36","article-title":"A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours","volume":"116","author":"Wilson","year":"2017","journal-title":"Br J Cancer."},{"issue":"1","key":"10.1016\/j.ygyno.2018.10.023_bb0350","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2018.10.023_bb0355","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2018.10.023_bb0360","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1073\/pnas.0904783107","article-title":"Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130","volume":"107","author":"Hegan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.ygyno.2018.10.023_bb0365","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"issue":"suppl_5","key":"10.1016\/j.ygyno.2018.10.023_bb0370","article-title":"953PA phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24\/AVANOVA1)","volume":"28","author":"Mirza","year":"2017","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2018.10.023_bb0375","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.ygyno.2018.10.023_bb0380","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.10.023_bb0385","series-title":"Press Release","article-title":"Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer","author":"AstraZeneca","year":"2018"},{"issue":"1","key":"10.1016\/j.ygyno.2018.10.023_bb0390","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG oncology\/GOG study","volume":"139","author":"Ferriss","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2018.10.023_bb0395","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818313064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818313064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:40:49Z","timestamp":1758771649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818313064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0090825818313064"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.10.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}